India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On

By Vikas Dandekar / Email the Author / PharmAsia News Nov. 30, 2011 4:40 PM GMT
India / Word Count: 1402 / Article # 28111126001

Executive Summary

Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1402-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to PharmAsia News will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 4

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article